Sirolimus as a second-line treatment for Graves' orbitopathy.

ABSTRACT:

Objectives

A beneficial effect of sirolimus in Graves' orbitopathy (GO) was reported, suggesting a possible use in clinical practice. We conducted an observational, single-centre, no-profit, clinical study to investigate the efficacy of sirolimus as a second-line treatment for moderate-to-severe, active GO compared with methylprednisolone.

Methods

Data from consecutive patients given sirolimus (2 mg orally on first day, followed by 0.5 mg/day for 12 weeks) or methylprednisolone [500 mg iv/weekly (6 weeks), 250 mg/weekly (6 weeks)] as a second-line treatment were collected and compared.

Primary objective

overall GO outcome at 24 weeks, based on a composite evaluation. Secondary objectives at 24 weeks: (1) improvement in quality of life, evaluated using a specific uesti

SUBMITTER: Lanzolla G 

PROVIDER: S-EPMC9525329 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature